CohBar Inc (CWBR)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Joseph J. Sarret
Employees:
10
1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK, CA, 94025
(650) 446-7888
Date | Ratio |
---|---|
2022-09-23 | 1:30 |
The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for NASH and obesity.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|